Recent progress in nanomedicine-based combination cancer therapy using a site-specific co-delivery strategy

2017 ◽  
Vol 5 (8) ◽  
pp. 1367-1381 ◽  
Author(s):  
Shiyang Shen ◽  
Meng Liu ◽  
Teng Li ◽  
Shiqi Lin ◽  
Ran Mo
Keyword(s):  
Cancer Therapy ◽  
Recent Progress ◽  
Review Article ◽  
Site Specific ◽  
Delivery Strategy ◽  
Combination Cancer Therapy ◽  
Delivery Strategies ◽  
A Site

This review article highlights the recent progresses in nanomedicine-based combination cancer therapy via site-specific co-delivery strategies.

Clustered nanobody–drug conjugates for targeted cancer therapy

2020 ◽  
Vol 56 (65) ◽  
pp. 9344-9347
Author(s):  
Tiantian Wu ◽  
Manman Liu ◽  
Hai Huang ◽  
Yaping Sheng ◽  
Haihua Xiao ◽  
...  
Keyword(s):  
Side Effects ◽  
Cancer Therapy ◽  
Drug Efficacy ◽  
Targeted Cancer Therapy ◽  
Site Specific ◽  
Drug Conjugate ◽  
Drug Conjugates ◽  
A Site

A novel clustered nanobody–drug conjugate is constructed by a site-specific ligation of a nanobody to dendrimeric-lysine, which enhances drug efficacy and reduces side-effects.

Recent progress of chemodynamic therapy-induced combination cancer therapy

Nano Today ◽  
2020 ◽  
Vol 35 ◽  
pp. 100946 ◽  
Author(s):  
Xianwen Wang ◽  
Xianyan Zhong ◽  
Zhuang Liu ◽  
Liang Cheng
Keyword(s):  
Cancer Therapy ◽  
Recent Progress ◽  
Combination Cancer Therapy

scholarly journals Recent Advances and Impact of Chemotherapeutic and Antiangiogenic Nanoformulations for Combination Cancer Therapy

Pharmaceutics ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 592
Author(s):  
Amit Kumar Rajora ◽  
Divyashree Ravishankar ◽  
Hongbo Zhang ◽  
Jessica M. Rosenholm
Keyword(s):  
Cancer Therapy ◽  
Combination Therapy ◽  
Physical Adsorption ◽  
Organic Polymer ◽  
Antitumor Effects ◽  
Recent Advances ◽  
Combination Cancer Therapy ◽  
Delivery Strategies ◽  
Tumor Growth And Metastasis ◽  
Multifunctional Nanocarriers

Traditional chemotherapy, along with antiangiogenesis drugs (combination cancer therapy), has shown reduced tumor recurrence and improved antitumor effects, as tumor growth and metastasis are often dependent on tumor vascularization. However, the effect of combination chemotherapy, including synergism and additive and even antagonism effects, depends on drug combinations in an optimized ratio. Hence, nanoformulations are ideal, demonstrating a great potential for the combination therapy of chemo-antiangiogenesis for cancer. The rationale for designing various nanocarriers for combination therapy is derived from organic (polymer, lipid), inorganic, or hybrid materials. In particular, hybrid nanocarriers that consist of more than one material construct provide flexibility for different modes of entrapment within the same carrier—e.g., physical adsorption, encapsulation, and chemical conjugation strategies. These multifunctional nanocarriers can thus be used to co-deliver chemo- and antiangiogenesis drugs with tunable drug release at target sites. Hence, this review attempts to survey the most recent advances in nanoformulations and their impact on cancer treatment in a combined regimen—i.e., conventional cytotoxic and antiangiogenesis agents. The mechanisms and site-specific co-delivery strategies are also discussed herein, along with future prospects.

Sequentially Site‐Specific Delivery of Apoptotic Protein and Tumor‐Suppressor Gene for Combination Cancer Therapy

Small ◽  
2019 ◽  
Vol 15 (40) ◽  
pp. 1902998 ◽  
Author(s):  
Xiaojie Chen ◽  
Qiuwen Zhu ◽  
Xiao Xu ◽  
Shiyang Shen ◽  
Ying Zhang ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Tumor Suppressor ◽  
Tumor Suppressor Gene ◽  
Suppressor Gene ◽  
Site Specific ◽  
Apoptotic Protein ◽  
Combination Cancer Therapy

Combination Cancer Therapy Using Multifunctional Liposomes

2020 ◽  
Vol 37 (2) ◽  
pp. 105-134 ◽  
Author(s):  
Ankit Jain ◽  
Ankita Tiwari ◽  
Amit Verma ◽  
Shivani Saraf ◽  
Sanjay Kumar Jain
Keyword(s):  
Cancer Therapy ◽  
Combination Cancer Therapy

Hyaluronan based Multifunctional Nano-carriers for Combination Cancer Therapy

2020 ◽  
Vol 20 ◽  
Author(s):  
Menghan Gao ◽  
Hong Deng ◽  
Weiqi Zhang
Keyword(s):  
Cancer Therapy ◽  
Combination Therapy ◽  
Cancer Cells ◽  
Drug Loading ◽  
Tumor Therapy ◽  
Drug Carriers ◽  
Functional Sites ◽  
Therapeutic Modalities ◽  
Combination Cancer Therapy ◽  
Targeting Strategy

: Hyaluronan (HA) is a natural linear polysaccharide that has excellent hydrophilicity, biocompatibility, biodegradability, and low immunogenicity, making it one of the most attractive biopolymers used for biomedical researches and applications. Due to the multiple functional sites on HA and its intrinsic affinity for CD44, a receptor highly expressed on various cancer cells, HA has been widely engineered to construct different drug-loading nanoparticles (NPs) for CD44- targeted anti-tumor therapy. When a cocktail of drugs is co-loaded in HA NP, a multifunctional nano-carriers could be obtained, which features as a highly effective and self-targeting strategy to combat the cancers with CD44 overexpression. The HA-based multidrug nano-carriers can be a combination of different drugs, various therapeutic modalities, or the integration of therapy and diagnostics (theranostics). Up to now, there are many types of HA-based multidrug nano-carriers constructed by different formulation strategies including drug co-conjugates, micelles, nano-gels and hybrid NP of HA and so on. This multidrug nano-carrier takes the full advantages of HA as NP matrix, drug carriers and targeting ligand, representing a simplified and biocompatible platform to realize the targeted and synergistic combination therapy against the cancers. In this review, recent progresses about HA-based multidrug nano-carriers for combination cancer therapy are summarized and its potential challenges for translational applications have been discussed.

Sign in / Sign up

Export Citation Format

Share Document